STAT+: What to expect from UniQure’s upcoming Huntington’s gene therapy readout 

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. Before the end of September, UniQure is expected to report four-year results from the closely tracked clinical trial of AMT-130, its gene therapy for Huntington’s disease. Three-year results were reported almost one year ago. The high dose of AMT-130, administered to 12 patients, slowed the progression of Huntington’s by 75% compared to match...